Literature DB >> 9132334

Retrobulbar optic neuritis after pamidronate administration in a patient with a history of cutaneous porphyria.

J M des Grottes1, M Schrooyen, J C Dumon, J J Body.   

Abstract

We describe the case of a patient who developed reversible retrobulbar optic neuritis after intravenous pamidronate therapy for established osteoporosis. This possible complication has never been previously reported and, since our patient had a history of porphyria, it suggests that bisphosphonates should be administered cautiously in patients with this disease.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9132334     DOI： 10.1007/bf02238770

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


  11 in total

1.  Ocular involvement in cutaneous porphyria. A clinical and histological report.

Authors:  D Sevel; D Burger
Journal:  Arch Ophthalmol       Date:  1971-05

2.  Bisphosphonates and iritis.

Authors:  E S Siris
Journal:  Lancet       Date:  1993-02-13       Impact factor: 79.321

Review 3.  The role of cytokines in the pathogenesis of inflammatory eye disease.

Authors:  D Wakefield; A Lloyd
Journal:  Cytokine       Date:  1992-01       Impact factor: 3.861

Review 4.  Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease.

Authors:  A Fitton; D McTavish
Journal:  Drugs       Date:  1991-02       Impact factor: 9.546

Review 5.  New bisphosphonates in osteoporosis.

Authors:  H Fleisch
Journal:  Osteoporos Int       Date:  1993       Impact factor: 4.507

6.  Pamidronate disodium and possible ocular adverse drug reactions.

Authors:  V Macarol; F T Fraunfelder
Journal:  Am J Ophthalmol       Date:  1994-08-15       Impact factor: 5.258

7.  Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate.

Authors:  D H Schweitzer; M Oostendorp-van de Ruit; G Van der Pluijm; C W Löwik; S E Papapoulos
Journal:  J Bone Miner Res       Date:  1995-06       Impact factor: 6.741

8.  Congenital erythropoietic porphyria: skeletal manifestations and effect of pamidronate treatment.

Authors:  M B Oliveri; C Mautalen; M Mega; E Rossi
Journal:  Bone       Date:  1994 Jan-Feb       Impact factor: 4.398

9.  Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

Authors:  J J Body; J C Dumon
Journal:  Ann Oncol       Date:  1994-04       Impact factor: 32.976

10.  Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause.

Authors:  D Thiébaud; P Burckhardt; J Melchior; P Eckert; A F Jacquet; P Schnyder; C Gobelet
Journal:  Osteoporos Int       Date:  1994-03       Impact factor: 4.507
View more
  3 in total

Review 1.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Multiple cranial neuropathies following zoledronic acid infusion: a relationship? Clinical features and pathogenic discussion concerning a case.

Authors:  S Deshayes; N Martin Silva; J Cogez; A Baldolli; S Fedrizzi; B Bienvenu; A Aouba
Journal:  Osteoporos Int       Date:  2016-03-15       Impact factor: 4.507

Review 3.  Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone.

Authors:  A J Coukell; A Markham
Journal:  Drugs Aging       Date:  1998-02       Impact factor: 3.923
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.